PDS Planning Inc Increases Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)

PDS Planning Inc boosted its position in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 389.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,254 shares of the company's stock after purchasing an additional 25,662 shares during the period. PDS Planning Inc's holdings in Dr. Reddy's Laboratories were worth $509,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of RDY. EverSource Wealth Advisors LLC increased its position in Dr. Reddy's Laboratories by 423.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock worth $29,000 after buying an additional 1,507 shares in the last quarter. POM Investment Strategies LLC increased its position in Dr. Reddy's Laboratories by 400.0% during the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock worth $36,000 after buying an additional 1,820 shares in the last quarter. Farther Finance Advisors LLC increased its position in Dr. Reddy's Laboratories by 461.0% during the fourth quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock worth $40,000 after buying an additional 2,093 shares in the last quarter. Glenmede Trust Co. NA purchased a new position in Dr. Reddy's Laboratories during the third quarter worth $207,000. Finally, Sierra Ocean LLC purchased a new position in Dr. Reddy's Laboratories during the fourth quarter worth $43,000. 3.85% of the stock is owned by hedge funds and other institutional investors.

Dr. Reddy's Laboratories Stock Up 1.1 %

NYSE:RDY traded up $0.15 during mid-day trading on Friday, hitting $13.73. The company had a trading volume of 1,569,630 shares, compared to its average volume of 1,262,059. The business has a fifty day simple moving average of $13.66 and a 200-day simple moving average of $14.71. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. Dr. Reddy's Laboratories Limited has a 1 year low of $12.50 and a 1 year high of $16.89. The firm has a market capitalization of $11.46 billion, a price-to-earnings ratio of 21.86 and a beta of 0.48.

Remove Ads

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. Equities analysts forecast that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on RDY. Nomura cut Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a report on Thursday, December 19th. StockNews.com cut Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a report on Friday, December 6th.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.